Last reviewed · How we verify
Infliximab; Gemcitabine
Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors.
Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors. Used for Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis.
At a glance
| Generic name | Infliximab; Gemcitabine |
|---|---|
| Sponsor | Centocor, Inc. |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
This prevents the inflammatory response mediated by TNF-alpha, which is involved in the pathogenesis of various autoimmune diseases.
Approved indications
- Rheumatoid Arthritis
- Crohn's Disease
- Ulcerative Colitis
Common side effects
- Infusion reaction
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infliximab; Gemcitabine CI brief — competitive landscape report
- Infliximab; Gemcitabine updates RSS · CI watch RSS
- Centocor, Inc. portfolio CI